Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep595 | Pituitary and Neuroendocrinology | ECE2020

Gallium-68 -DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas

M. Boertien Tessel , Booij Jan , Majoie Charles BLM , Drent ML , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Stokkel Marcel PM , Bisschop Peter H , Fliers Eric

Background: Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express various somatostatin receptor (SSTR) subtypes, but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy (Octreoscan) in vivo. The aim of this study was to assess SSTR expression in NFMA <em...

ea0099rc5.2 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

Lanreotide in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): A randomised, double-blind, placebo-controlled trial

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M. , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Weterings Annick J. , Vink Juan M. , Tanck Michael W.T. . , Fliers Eric , Bisschop Peter H.

Background: Patients with non-functioning pituitary macroadenoma (NFMA) currently have no established medical treatment options. Somatostatin analogues may decrease tumour size, but randomised controlled trials are lacking. In vivo somatostatin receptor assessment with 68Ga-DOTATATE PET could help in selecting patients for treatment. We aimed to determine the effect of the somatostatin analogue lanreotide on tumour size in patients with a 68Ga-DOTATATE PE...